PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.

Area of Science:

• Oncology
• Genetics
• Immunotherapy

Background:

• Missense mutations in the polymerase epsilon (POLE) gene can cause proofreading defects, leading to increased tumor mutation rates.
• These POLE mutations have been linked to enhanced sensitivity to checkpoint blockade immunotherapy, but response rates vary.
• Many POLE-mutated tumors do not benefit from current immunotherapy treatments.

Purpose of the Study:

• To investigate the efficacy of nivolumab in patients with advanced mismatch repair-proficient POLE-mutated solid tumors.
• To identify specific POLE mutation variants associated with immunotherapy response.
• To determine if POLE proofreading deficiency can serve as a biomarker for anti-PD-1 therapy.

Main Methods:

• Prospective multicenter clinical trial assessing nivolumab efficacy.
• Analysis of patients with advanced mismatch repair-proficient POLE-mutated solid tumors.
• Correlation of specific POLE mutation types with tumor mutational burden, T-cell infiltrates, and response to anti-PD-1 monotherapy.

Main Results:

• Only POLE pathogenic mutations in the exonuclease domain's DNA binding or catalytic sites led to high mutational burden and specific mutational signatures.
• These specific POLE mutations were associated with high T-cell infiltrates and a high response rate to anti-PD-1 monotherapy.
• POLE mutations not affecting proofreading did not benefit from PD-1 blockade.

Conclusions:

• Specific DNA repair defects, like POLE proofreading deficiency, can sensitize tumors to immunotherapy.
• POLE proofreading deficiency is a novel, tissue-agnostic biomarker for predicting response to PD-1 checkpoint blockade therapy.
• This finding highlights the importance of specific genetic alterations in guiding cancer treatment decisions.